ClinicalTrials.gg
CompletedNCT05084222EASYRELIEFUpdated Sep 5, 2023

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing

A Phase 4 interventional study of Buventol® Easyhaler® 200 µg/inhalation dmDPI and Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 2 sites in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by Orion Corporation, Orion Pharma · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Enrollment
3rd of 19
180 · median 72
Started
2021
with 1 other
Phase 4
2 of 21
none open now
Registered
21st of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 4, and was the 21st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

The study compares Buventol® Easyhaler® and Bufomix® Easyhaler® to the current standard treatment during methacholine challenge test. The trial will also provide inspiratory flow profile data for Easyhaler inhaler.

This trial is designed to provide a further evidence for the use of Easyhaler in diagnostic bronchial challenge tests and on the use of Easyhaler inhaler during obstructive event.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written (IC) obtained.
  2. Finnish speaking adult (≥ 18 years old) subject indicated for methacholine challenge test.
  3. The subject experiences drop ≥ 20% compared to post-diluent spirometry.

Exclusion criteria

Exclusion Criteria:

  1. Subjects not eligible for methacholine challenge test for example for any of the following reasons:

    • Any respiratory infection within 2 weeks, or severe respiratory infection within 4 weeks before the study visit
    • \< 60% of predicted or \< 1.0 l
    • Inability to perform acceptable and repeatable spirometry manoeuvres throughout the test procedure
    • Uncontrolled hypertension
    • Acute chest pain or unstable angina pectoris
    • Significant cardiac arrhythmias
    • Pneumothorax or recent bronchoscopy
    • Myocardial infarction or stroke in last 3 months
    • Known aortic aneurysm
    • Recent eye surgery or intracranial pressure elevation risk
    • Cholinesterase inhibitor medication
    • Pregnant or lactating females
  2. Subjects who have used the following treatments before the study visit:

    • Short-acting β-agonists within 12 h
    • Long-acting β-agonists within 36 h
    • Ultra-long-acting β-agonists within 48 h
    • Long-acting anti-muscarinic agents within 168 h
    • Short-acting anticholinergics within 12 h
    • Oral theophylline within 24 h
    • Inhaled , leukotriene receptor antagonists and chromones within 4 weeks
  3. Known to the active substance(s) or the of the study treatments (for example severe milk allergy, lactose contains small amounts of milk protein).
  4. Administration of another medicinal product within 30 days before the study visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Buventol® Easyhaler® 200 µg/inhalation dmDPI

    400 μg of salbutamol from Buventol Easyhaler is administered as two inhalations.

    Drug: Buventol® Easyhaler® 200 µg/inhalation dmDPI

  • Experimental
    Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI

    320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.

    Drug: Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI

  • Active comparator
    Ventoline® Evohaler® 100 µg/inhalation pMDI

    400 μg of salbutamol from Ventoline Evohaler is administered via Volumatic spacer as four inhalations.

    Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI

Interventions

  • DrugBuventol® Easyhaler® 200 µg/inhalation dmDPI

    Two doses will be administered

    Also known as: Salbutamol 200 µg/dose dmDPI

  • DrugBufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI

    Two doses will be administered

    Also known as: Budesonide/formoterol 160/4.5 µg/inhalation dmDPI

  • DrugVentoline® Evohaler® 100 µg/inhalation pMDI

    Four doses will be administered via Volumatic spacer

    Also known as: Salbutamol 100 µg/dose MDI

06

What researchers measure

Primary outcomes

  1. Forced expiratory volume in one second (FEV1)

    Mean change in FEV1 from post-diluent to FEV1 after the first dose of reliever.

    Time frame: 10 minutes

Secondary outcomes

  1. Number of subjects who recover from bronchoconstriction after first dose

    Proportion of the subjects who recover to FEV1 \> -10% compared to post-diluent FEV1 after first dose of reliever.

    Time frame: 10 minutes

  2. Forced expiratory volume in one second (FEV1)

    Relative recovery of FEV1 after the study treatment dosing when compared to post-diluent FEV1.

    Time frame: 10 minutes

  3. Number of subjects who recover from bronchoconstriction after second dose

    Proportions of subjects reaching FEV1 \> -10% of post-diluent value after second dose of reliever.

    Time frame: 20 minutes

Other outcomes

  1. Number of patients needing medical attention

    Proportion of subjects needing medical attention after study treatment

    Time frame: After study treatment administration until study completion (an average of 2.5 hours)

  2. Inhalation profile via Easyhaler

    Time-inspiratory flow -curve via Easyhaler measured with spirometer.

    Time frame: Before methacholine challenge and 10 minutes after the subject experiences FEV1 drop ≥ 20% compared to post-diluent spirometry

07

Study locations

2 sites
  • Helsinki University Hospital
    Helsinki, 00029, Finland
  • Tampere University Hospital
    Tampere, 33520, Finland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jun 2023, 19 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 19 months is close to that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Oct 19, 2021
StartActual
Nov 11, 2021
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Last update
Sep 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05084222
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Nov 11, 2021
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Sep 5, 2023

Study contacts

Lauri Lehtimäki
principal investigator · Tampere University Hospital, Finland

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion